Gordon Research Conferences
Meeting Details
Search:
  GO

Antibody Biology & Engineering
Gordon Research Conference

Antibodies as Change Agents – Biological Diversity and Synergies

Dates

March 25-30, 2018

Location

Renaissance Tuscany Il Ciocco
Lucca (Barga), Italy Site Information

Organizers

Chairs:
Mark Hogarth & James Ernst

Vice Chair:
Jeanette Leusen

Application Deadline

Applications for this meeting must be submitted by February 25, 2018. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.

Meeting Description

Antibodies are multifaceted proteins that are capable of an array of important functions. They have a major part to play in immune protection against invading pathogens, and have a central role in the protective response induced by vaccination. Our understanding of the critical pathophysiology of antibodies in clinically important inflammatory and autoimmune diseases, is increasingly applied to the design of highly effective therapeutic molecules. Indeed, antibodies represent the largest class of biologics that are currently in development or approved by major pharmaceutical regulatory organizations for the treatment of an amazingly broad variety of diseases.

The 2018 Antibody Biology and Engineering Gordon Conference will present in-depth coverage of recent advances in this exciting field, in an informal setting designed to maximize interaction. The conference will bring together leading researchers from academia and the biopharmaceutical industry, providing an ideal opportunity for top researchers from around the world to present and discuss cutting-edge data.

Fusing new developments in basic science with high-impact translational and clinical research, the meeting will provide a stimulating program featuring an international mix of established and upcoming researchers. A major emphasis will be on mechanisms of antibody action in health and disease. Key topics will include antibody diversity, structure-function relationships, immunoglobulin effector function, antibody synergies and cross talk, recruitment of host factors and alternative antibody-dependent responses. Significant attention will also be focused on preclinical evaluation of therapeutic antibody candidates for indications including infectious disease, autoimmune disease and immuno-oncology.

The GRC will be preceded by a Gordon Research Seminar (GRS). The Antibody Biology and Engineering GRS is designed to further facilitate the participation of graduate students and postdoctoral researchers. Planned by, and for trainees, the GRS provides an opportunity for junior researchers to present seminars and posters in a supportive, interactive environment.

Related Meeting

This GRC will be held in conjunction with the "Antibody Biology & Engineering" Gordon Research Seminar (GRS). Those interested in attending both meetings must submit an application for the GRS in addition to an application for the GRC. Refer to the associated GRS program page for more information.

Contributors

Gordon Research Conferences

Session Titles

The Conference will consist of nine sessions, on the topics listed below. The Conference Chair is currently developing their preliminary program, which will include the names of the invited speakers and discussion leaders for each of these sessions. The preliminary program will be available by July 1, 2017. Please check back for updates.

  • Keynote Session: Therapeutic Antibodies
  • Antibody Properties and Diversity
  • Structure Function Relations
  • Immunoglobulin Effector Function
  • Antibody Cross Talk
  • Orchestrating Antibody Responses
  • Alternative Antibody Dependent Responses
  • Antibodies Therapeutics as Agents of Clinical Change
  • In Vivo and In Vitro Pre-Clinical Evaluation
© 2017 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter